GeneDx (NASDAQ:WGS) Rating Increased to Hold at Zacks Research

Zacks Research upgraded shares of GeneDx (NASDAQ:WGS) from a strong sell rating to a hold rating in a research report report published on Tuesday morning,Zacks.com reports.

Several other equities analysts also recently commented on WGS. Craig Hallum reissued a “buy” rating and issued a $85.00 price objective on shares of GeneDx in a research note on Tuesday, May 5th. Wall Street Zen cut shares of GeneDx from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Piper Sandler reiterated an “overweight” rating and set a $63.00 price target (up from $50.00) on shares of GeneDx in a report on Tuesday, June 23rd. Weiss Ratings cut GeneDx from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, June 1st. Finally, TD Cowen reissued a “buy” rating on shares of GeneDx in a report on Wednesday, July 15th. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $87.43.

GeneDx Stock Up 2.9%

Shares of NASDAQ WGS opened at $63.69 on Tuesday. The company has a market cap of $1.89 billion, a price-to-earnings ratio of -23.76 and a beta of 1.90. The company has a current ratio of 3.09, a quick ratio of 2.95 and a debt-to-equity ratio of 0.38. GeneDx has a 12 month low of $32.21 and a 12 month high of $170.87. The stock has a 50-day moving average price of $59.88 and a two-hundred day moving average price of $70.44.

GeneDx (NASDAQ:WGS) last posted its quarterly earnings results on Monday, May 4th. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.22). GeneDx had a negative net margin of 17.58% and a positive return on equity of 9.15%. The company had revenue of $102.25 million during the quarter, compared to analyst estimates of $112.46 million. During the same quarter in the previous year, the business posted ($0.23) earnings per share. As a group, analysts forecast that GeneDx will post -1 earnings per share for the current fiscal year.

Insider Buying and Selling

In other GeneDx news, Director Keith A. Meister bought 533,758 shares of the business’s stock in a transaction that occurred on Thursday, May 7th. The shares were acquired at an average cost of $37.86 per share, for a total transaction of $20,208,077.88. Following the transaction, the director directly owned 3,761,908 shares in the company, valued at approximately $142,425,836.88. This represents a 16.53% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Casdin Capital, Llc bought 185,000 shares of GeneDx stock in a transaction on Tuesday, May 19th. The shares were acquired at an average cost of $42.60 per share, for a total transaction of $7,881,000.00. Following the completion of the acquisition, the director directly owned 3,367,164 shares in the company, valued at approximately $143,441,186.40. The trade was a 5.81% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders purchased 2,256,420 shares of company stock valued at $93,144,340 and sold 19,135 shares valued at $1,128,499. 25.17% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of WGS. Handelsbanken Fonder AB grew its position in shares of GeneDx by 17.0% in the 2nd quarter. Handelsbanken Fonder AB now owns 6,200 shares of the company’s stock valued at $426,000 after buying an additional 900 shares during the last quarter. Assenagon Asset Management S.A. lifted its stake in shares of GeneDx by 219.0% in the second quarter. Assenagon Asset Management S.A. now owns 303,433 shares of the company’s stock worth $20,831,000 after acquiring an additional 208,305 shares during the period. Bank of America Corp DE lifted its stake in shares of GeneDx by 77.5% in the first quarter. Bank of America Corp DE now owns 234,606 shares of the company’s stock worth $15,066,000 after acquiring an additional 102,456 shares during the period. California State Teachers Retirement System boosted its holdings in GeneDx by 31.2% in the first quarter. California State Teachers Retirement System now owns 25,045 shares of the company’s stock valued at $1,608,000 after acquiring an additional 5,951 shares during the last quarter. Finally, Ashford Capital Management Inc. increased its position in GeneDx by 31.9% during the 1st quarter. Ashford Capital Management Inc. now owns 174,512 shares of the company’s stock valued at $11,207,000 after purchasing an additional 42,186 shares during the period. 61.72% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting GeneDx

Here are the key news stories impacting GeneDx this week:

• Positive Sentiment: GeneDx has an average analyst recommendation of “Moderate Buy,” suggesting some analysts continue to see recovery or long-term value in the company despite recent volatility. GeneDx analyst recommendation
• Negative Sentiment: Multiple law firms announced or promoted a securities class action against GeneDx and certain officers. The case covers investors who purchased shares from April 16, 2025, through May 4, 2026, with an August 3, 2026 deadline to seek lead-plaintiff status. The repeated notices increase the visibility of the legal risk and may weigh on investor confidence. GeneDx class action announcement
• Negative Sentiment: The allegations focus on claims that GeneDx concealed deteriorating reimbursement rates and margin compression. Other notices allege that the company overstated the performance and strategic benefits of its Fabric Genomics acquisition, which allegedly resulted in a $31.2 million write-off and contributed to a roughly 49% stock decline. These are allegations, not proven findings. GeneDx shareholder alert
• Negative Sentiment: The litigation headlines add to existing fundamental concerns: GeneDx’s latest reported quarter missed both revenue and EPS expectations, and analysts expect a full-year loss. Potential legal costs, settlement exposure, and additional scrutiny could further pressure the valuation. GeneDx deadline alert

GeneDx Company Profile

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.